Composition for determining whether nucleic acid is methylated and method for determining whether nucleic acid is methylated

By using a combination of methylated and non-methylated primers, the primer annealing temperature and concentration ratio are adjusted, and the problems of insufficient sensitivity and low specificity of DNA methylation assays in the prior art are solved, thus achieving low ratio of methylation High sensitivity detection and accurate measurement of the basing level.

CN119095987APending Publication Date: 2024-12-06LEPIDYNE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036464.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-26
Filing Date
2023-04-07
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing DNA methylation assays have problems such as insufficient sensitivity, low specificity, high cost and sample volume limitation. Especially when detecting methylation levels at very low rates, it is difficult for conventional methods to accurately measure.

Method used

Using a combination of methylated primers and non-methylated primers, the primer set of target sites is designed to specifically amplify DNA by adjusting the primer annealing temperature and concentration ratio, avoid non-specific amplification, and achieve high sensitivity methyl groups. Determination of state of synthesis.

Benefits of technology

High sensitivity detection of very low-rate methylation levels is achieved, reducing costs, improving assay specificity, and enabling accurate measurement of methylation status under trace DNA conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095987A_ABST
    Figure CN119095987A_ABST
Patent Text Reader

Abstract

The present application relates to a composition for determining whether a nucleic acid is methylated and a method for determining whether a nucleic acid is methylated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to a composition for determining whether a nucleic acid is methylated and a method for determining whether a nucleic acid is methylated. Background Art

[0002] As a method for measuring the methylation level of a DNA sample, there are qMSP, MethyLight and MS-HRM, etc., and all methods are constructed to relatively determine the methylation level of each sample. For example, the qMSP method measures the methylation level by using primers that only bind to methylated (or non-methylated) templates to the same amount of DNA samples, and measuring the PCR Cq value of the DNA amount produced by amplified DNA under corresponding conditions in the sample. The Methylight method combines the DNA in the amplified DNA that specifically binds to the marker to be tested with the probe by adding a probe to the qMSP, thereby improving the specificity of the measurement. In addition, the MS-HRM method uses primers that can bind to the template strain regardless of the methylation state of the DNA sample, and confirms the signal of the melting point difference of the amplified product based on the temperature increase caused by including a certain number of CpGs in the region other than the primer binding region of the amplified product.

[0003] qMSP and MethyLight analysis have almost no restrictions on primer design, and have the advantages of simple experimental design and can achieve relatively high sensitivity. However, additional control marker analysis is required to correct the amount of sample used for analysis, and the results are used to correct the measured values. The quantitative analysis is indirect and restrictive, and the frequency of type II errors is high. In addition, the biased amplification of specific templates has the disadvantage of reduced specificity because it may increase the frequency of nonspecific amplification of each DNA sample. In the case of developing MethyLight as a method to compensate for specificity, fluorescent probes that can specifically bind to the amplification product are also required, which has the disadvantages of increasing costs and increasing the difficulty of analytical test design. In addition, in many cases, the specific binding of the probe has limitations, that is, it is difficult to analyze very small amounts of samples because this reduces the amplification efficiency of PCR.

[0004] In the case of MS-HRM analysis, since methylated and non-methylated nucleic acids are amplified simultaneously in the same test tube, the methylation level of a DNA sample can be quantitatively measured more intuitively than with MSP without the need for additional control marker analysis. However, it is not easy to develop a specific analysis method due to design restrictions that CpG should not be included in the primers or non-specific bases should be included in the primer design. In addition, in the case where CpG is not included in the primers, there is a problem of biased binding to the non-methylated strand compared to the methylated strand, and type I errors may occur due to the non-methylation bias of the sample verification results, and in experiments that require sensitive methylation abnormality measurement (such as cancer diagnosis), there is a problem of low methylation ratio measurement values ​​in actual samples or inaccurate results. Summary of the invention

[0005]

Technical issues

[0006] One embodiment of the present application is to establish a method for determining methylation status, which makes up for the shortcomings of conventional experimental verification methods. The method for determining methylation status according to the embodiment of the present application can measure the relative methylation ratio without analyzing control markers in the same test tube, without using probes that interfere with amplification efficiency, and with high detection sensitivity. In addition, in order to measure very low ratios of methylation levels in biological samples such as blood, the amplification efficiency of methylated and non-methylated DNA can be adjusted.

[0007] The composition and method according to one embodiment of the present application use methylated primers and non-methylated primers together, so that non-specific amplification products are not generated and the methylation level of the sample can be measured more sensitively than conventional PCR-based analysis methods even under conditions where the desired target nucleic acid is present in trace amounts.

[0008] One embodiment of the present application is to provide a composition for determining whether a nucleic acid to be tested is methylated, and to provide a method for determining whether a nucleic acid to be tested is methylated with high sensitivity by making up for the deficiencies of conventional methods for measuring the methylation level of DNA samples.

[0009] Another embodiment of the present application is to provide a primer design strategy and optimization method, which can be universally applied to various DNA methylation markers.

[0010] Other embodiments of the present application are to provide a method for diagnosing cancer, a method for providing information for diagnosing cancer, a composition for diagnosing cancer, or a kit for diagnosing cancer, which measures the DNA methylation level of ctDNA (circulating tumor DNA) present in small amounts in cancer patients in cfDNA (cell-free DNA) present in a biological sample (such as blood), wherein the measurement is performed in the sample by a semi-quantitative method, and based on this, high sensitivity and specificity are achieved.

[0011]

Technical solution

[0012] One embodiment of the present application relates to a composition for determining whether a nucleic acid to be tested is methylated, which comprises a primer set for amplifying a target site of the nucleic acid to be tested.

[0013] Another embodiment of the present application relates to a method for determining whether a test nucleic acid is methylated, the method comprising: a step of modifying the methylated test nucleic acid and the non-methylated test nucleic acid to be different from each other in a biological sample containing the test nucleic acid; and a step of amplifying the target site by treating the biological sample with the composition.

[0014] Hereinafter, the present application will be described in more detail.

[0015] One embodiment of the present application relates to a novel method for measuring the methylation level of a nucleic acid to be tested, which method makes up for the insufficiency of a conventional experimental verification method for measuring the methylation level of a nucleic acid to be tested. Specifically, when designing MS-HRM primers, a methylation primer comprising a CpG recognition site is used, and the CpG recognition site recognizes the CpG sequence in the primer, and in order to prevent only amplification of a methylated template, a non-methylation primer comprising a TpG recognition site for amplification of a non-methylated template is used simultaneously, and the TpG recognition site recognizes the TpG sequence. Then, in order to prevent the relatively low sensitivity of MS-HRM and the biased amplification of the primer comprising TpG, a method for increasing the binding chance of the primer comprising CpG and reducing the binding chance of the primer comprising TpG by adjusting the temperature of the primer annealing step of PCR is constructed.

[0016] In this specification, the term "methylation" refers to the attachment of a methyl group to a base constituting DNA. For example, methylation may occur in cytosine at a specific CpG site of a specific gene or nucleic acid.

[0017] In this specification, the term "methylation" or "methylation status" refers to whether methylation is present in the cytosine of a specific CpG site of a specific gene or nucleic acid. Specifically, it refers to the presence or absence of 5-methylcytosine in at least one CpG dinucleotide in the base sequence.

[0018] In the present specification, the term "methylation level" or "methylation degree" refers to the amount of methylation present in the base sequence of the nucleic acid to be tested.

[0019] In this specification, the term "CpG site" or "CpG sequence" refers to a CpG site present in the base sequence of a specific gene or nucleic acid. A gene is a concept of a whole series of constituent units, which are necessary for expression and are operably connected to each other and may include a promoter region, a protein coding region (open reading frame, ORF) and a terminator region. Therefore, a CpG site may be present in the promoter region, the protein coding region (open reading frame, ORF) or the terminator region of the corresponding gene, etc. For example, it may be a CpG site present in the promoter region of a gene.

[0020] In this specification, the term "nucleic acid" is a polymeric form of nucleotides, representing ribonucleotides or deoxyribonucleotides, and includes polynucleotides, oligonucleotides, oligomers, oligomers (oligos), coding sequences, etc. The meaning of nucleic acid may include single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or purine and pyrimidine bases, or polymers with other natural, chemically or biochemically modified, non-natural or derived nucleotide bases.

[0021] In the present specification, when it is described that “comprising” a component, it does not mean that other components are excluded, but other components may be further included unless specifically mentioned otherwise.

[0022] In the present specification, nucleic acids are written from left to right in 5' to 3' direction, respectively, unless otherwise indicated.

[0023] In this specification, the singular includes plural objects unless the context clearly indicates otherwise.

[0024] One embodiment of the application relates to a composition for determining whether a nucleic acid to be tested is methylated, which comprises a primer set for amplifying a target site of the nucleic acid to be tested, or a test kit for determining whether the nucleic acid to be tested is methylated comprising the composition. The primer set may include a forward primer and a reverse primer, and one of the forward primer and the reverse primer may include a methylated primer and a non-methylated primer, and the other may be a universal primer. The methylated primer may include a CpG recognition site for the CpG sequence of the nucleic acid to be tested, and the non-methylated primer may include a TpG recognition site for the TpG sequence of the nucleic acid to be tested, and the TpG sequence may be converted by the CpG sequence of the nucleic acid to be tested. Universal primers refer to primers that can specifically identify and bind to nucleic acid to be tested regardless of whether the nucleic acid to be tested is methylated.

[0025] Another embodiment of the present application relates to a method for determining whether a nucleic acid to be tested is methylated, the method comprising: a step of modifying a methylated nucleic acid to be tested and a non-methylated nucleic acid to be tested to be different from each other, wherein the nucleic acid to be tested is contained in a biological sample; and a step of amplifying a target site by treating the biological sample with the composition. The modification step can be performed by treating the biological sample with a reagent, and the reagent modifies the methylated nucleic acid to be tested and the non-methylated nucleic acid to be tested to be different from each other.

[0026] The target site is a site of interest for determining whether the nucleic acid to be tested is methylated, and may contain at least one CpG sequence. The size of the target site may be 50 to 150 bp, 50 to 140 bp, 50 to 130 bp, 50 to 120 bp, 50 to 110 bp, 50 to 100 bp, 60 to 150 bp, 60 to 140 bp, 60 to 130 bp, 60 to 120 bp, 60 to 110 bp or 60 to 100 bp.

[0027] For example, the target site may include a biomarker. Specifically, the biomarker may be a methylation biomarker. The methylation biomarker refers to a biomarker that is associated with a specific disease based on whether the biomarker is methylated. More specifically, the methylation biomarker refers to a biomarker that is associated with a specific disease based on the epigenetic changes that occur when a methyl group (CH3) is added to the C (cytosine) of CG in the base sequence of the biomarker.

[0028] In one embodiment of the present application, the target site may include a biomarker present in a CpG island. The primer set according to the embodiment of the present application includes (1) a methylated forward primer, an unmethylated forward primer and a universal reverse primer; or (2) a universal forward primer, a methylated reverse primer and an unmethylated reverse primer, and even when it is difficult to prepare a universal primer, for example, when the sequence complexity is reduced by sulfite treatment, or when the biomarker is present in a CpG island where adjacent sites change together, it is also possible to accurately determine whether the target site is methylated. Specifically, in conventional HRM analysis methods, when the sequence complexity of gDNA is reduced by sulfite treatment and non-specific reactions occur frequently, or in particular, in the case of CpG islands, when it is difficult to prepare a CpG-free MIP (methylation-independent primer; universal primer), analysis becomes difficult, but the present application can ensure the freedom of primer design by using methylated primers and unmethylated primers in primers in one direction at the same time, and can accurately determine whether the target site is methylated while inducing specific binding of the target.

[0029] The methylated primer, specifically, the methylated forward primer or the methylated reverse primer, comprises a CpG recognition site for recognizing the CpG sequence of the nucleic acid to be tested, and the non-methylated primer, specifically, the non-methylated forward primer or the non-methylated reverse primer, comprises a TpG recognition site for recognizing the TpG sequence of the nucleic acid to be tested, in which the CpG sequence is converted. The TpG sequence is a CpG sequence converted by a reagent that modifies the methylated nucleic acid to be tested and the non-methylated nucleic acid to be tested into different ones. For example, the modifier can convert non-methylated cytosine residues into thymine. As an example, the modifier can be at least one selected from the group consisting of sulfurous acid, bisulfite, hydrogensulfite and pyrosulfite.

[0030] When the template is treated with a reagent that modifies the methylated nucleic acid to be detected and the non-methylated nucleic acid to be detected to be different from each other, if the CpG cytosine of the template is methylated, the CpG cytosine is not converted into thymine, and if the CpG cytosine is not methylated, the CpG cytosine is converted into thymine.

[0031] The CpG recognition site of the methylation primer can recognize the CpG sequence of the methylated nucleic acid to be detected. For example, the CpG recognition site can include a CG sequence.

[0032] The TpG recognition site of the non-methylated primer can recognize a TpG sequence, which is a CpG sequence of the non-methylated nucleic acid to be tested converted by a reagent that modifies the methylated nucleic acid to be tested and the non-methylated nucleic acid to be tested into different CpG sequences. For example, the TpG recognition site can include a TG sequence.

[0033] The CpG recognition site and the TpG recognition site are respectively located near the 3' end of the methylated primer and the non-methylated primer, and can specifically recognize the methylated nucleic acid to be tested and the non-methylated nucleic acid to be tested that are converted by reagents that modify the methylated nucleic acid to be tested and the non-methylated nucleic acid to be tested into different ones. For example, the CpG recognition site and the TpG recognition site can be located within 40, 35, 30, 25, 20, 10, 9, 8, 7, 6, 5, 4, 3 or 2 bases of the 3' end of the methylated primer and the non-methylated primer, or at its 3' end.

[0034] Compared with methylated primers, non-methylated primers have lower Tm values, so in order to compensate for this, by adding nucleotides at the 5' ends of non-methylated primers, the Tm of methylated primers and non-methylated primers can be similarly designed. For example, by further including nucleotides at the 5' end, the non-methylated primer can have more nucleotides than the methylated primer. For example, compared with the methylated primer, the non-methylated primer can further include 1 to 5, 1 to 4, 1 to 3, 1 to 2 or 1 nucleotides at the 5' end. For example, the Tm difference between the methylated primer and the non-methylated primer can be 15°C or lower, 14°C or lower, 13°C or lower, 12°C or lower, 11°C or lower, 10°C or lower, 9°C or lower, 8°C or lower, 7°C or lower, 6°C or lower, 5°C or lower, 4°C or lower, 3°C or lower, 2°C or lower or 1.5°C or lower.

[0035] Primer set comprises forward primer and reverse primer, and when methylation primer and non-methylation primer are forward primer, the primer of reverse direction is reverse primer, and when methylation primer and non-methylation primer are reverse primer, the primer of reverse direction is forward primer.The primer of described reverse direction is the universal primer that can combine methylation nucleic acid to be measured and non-methylation nucleic acid to be measured.Therefore, the primer of described reverse direction (universal primer) can not comprise CpG binding site, but when inevitably comprising CpG binding site in the primer of reverse direction due to the structure of nucleic acid to be measured, 5 ' end region can comprise 5 or less, 4 or less, 3 or less, 2 or less, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or as an example, 1 CpG binding site.But, now, preferably the primer of reverse direction is designed to have Tm similar to methylation primer and non-methylation primer.

[0036] The sizes of the methylated primer, the unmethylated primer and the reverse primer may include 15 to 40, 15 to 35, 15 to 30, 15 to 25, 18 to 40, 18 to 35, 18 to 30, 18 to 25, 20 to 40, 20 to 35, 20 to 30 or 20 to 25 bases.

[0037] The methylated primer, the unmethylated primer and the reverse primer can be combined with the nucleic acid to be tested, and the nucleic acid to be tested is converted by a reagent that modifies the methylated nucleic acid to be tested and the unmethylated nucleic acid to be tested into different ones by containing 1 or more, 2 or more, or 3 or more non-CpG cytosines.

[0038] The Tm of the methylated primer, the non-methylated primer and the reverse direction primer can be 50 to 80°C, 50 to 75°C, 50 to 70°C, 50 to 65°C, 55 to 80°C, 55 to 75°C, 55 to 70°C, 55 to 65°C, 60 to 80°C, 60 to 75°C, 60 to 70°C or 60 to 65°C.

[0039] The composition according to the embodiments of the present application may include a concentration ratio of 100:1 to 1:100, 100:1 to 1:50, 100:1 to 1:20, 100:1 to 1:10, 100:1 to 1:5, 100:1 to 1:1, 100:1 to less than 1:1, 100:1 to 1.3:1, 100:1 to 1.5:1, 100:1 to 2:1, 100:1 to 2.5:1, 100:1 to 3:1, 100:1 to 3.5:1, 100:1 to 4:1, 50:1 to 1:100. , 50:1 to 1:50, 50:1 to 1:20, 50:1 to 1:10, 50:1 to 1:5, 50:1 to 1:1, 50:1 to less than 1:1, 50:1 to 1.3:1, 50:1 to 1.5:1, 50:1 to 2:1, 50:1 to 2.5:1, 50:1 to 3:1, 50:1 to 3.5:1, 50:1 to 4:1, 10:1 to 1:100, 10:1 to 1:50, 10:1 to 1:20, 10:1 to 1:10, 10:1 to 1:5, 10:1 to 1:1, 10:1 to less than 1:1, 10:1 to 1.3:1, 10:1 to 1.5:1, 10:1 to 2:1, 10:1 to 2.5:1, 10:1 to 3:1, 10:1 to 3.5:1, 10:1 to 4:1, 5:1 to 1:100, 5:1 to 1:50, 5:1 to 1:20, 5:1 to 1:10, 5:1 to 1:5, 5:1 to 1:1, 5:1 to less than 1:1, 5:1 to 1.3:1, 5:1 to 1.5:1, 5:1 to 2:1, 5:1 to 2.5:1, 5:1 to 3:1 , 5:1 to 3.5:1, 5:1 to 4:1, 4.5:1 to 1:100, 4.5:1 to 1:50, 4.5:1 to 1:20, 4.5:1 to 1:10, 4.5:1 to 1:5, 4.5:1 to 1:1, 4.5:1 to less than 1:1, 4.5:1 to 1.3:1, 4.5:1 to 1.5:1, 4.5:1 to 2:1, 4.5:1 to 2.5:1, 4.5:1 to 3:1, 4.5:1 to 3.5:1, or 4.5:1 to 4:1.

[0040] For example, the concentration of the non-methylated primer can be 100% or less, less than 100%, 99.99% or less, 99.95% or less, 99.9% or less, 99% or less, 98% or less, 97% or less, 96% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 40% or less, 30% or less or 25% or less of the concentration of the methylated primer. And as an example, it can be 50% or less.

[0041] The composition and method according to the embodiments of the present application can accurately determine whether the nucleic acid to be tested is methylated without using a fluorescent probe for detecting the amplification product. Therefore, the composition according to the embodiments of the present application may not include a fluorescent probe. In addition, the method according to the embodiments of the present application may not use a fluorescent probe.

[0042] The nucleic acid to be tested for methylation by the composition and method according to the embodiments of the present application may be contained in a biological sample. The biological sample may contain at least one selected from the group consisting of blood, serum, tissue, cell, feces and urine.

[0043] The composition and method according to the embodiments of the present application can determine whether the nucleic acid to be detected is methylated with high sensitivity, even when the concentration of the methylated nucleic acid to be detected in the biological sample is very low.

[0044] For example, the concentration of the methylated nucleic acid to be determined in the biological sample can be 100 ng / μl or less, 90 ng / μl or less, 80 ng / μl or less, 70 ng / μl or less, 60 ng / μl or less, 50 ng / μl or less, 40 ng / μl or less, 30 ng / μl or less, 20 ng / μl or less, 15 ng / μl or less, 10 ng / μl or less, 9 ng / μl or less, 8 ng / μl or less, 7 ng / μl or less, 6 ng / μl or less, 5 ng / μl or less, 4 ng / μl or less, 3 ng / μl or less, 2 ng / μl or less, l or less, 1.5ng / μl or less, 1ng / μl or less, 0.5ng / μl or less, 0.4ng / μl or less, 0.3ng / μl or less, 0.2ng / μl or less, 0.1ng / μl or less, 0.05ng / μl or less, 0.04ng / μl or less, 0.03ng / μl or less, 0.02ng / μl or less, 0.01ng / μl or less, 0.009ng / μl or less, 0.008ng / μl or less, 0.007ng / μl or less, 0.006ng / μl or less, or 0.005ng / μl or less.

[0045] For example, the biological sample contains methylated nucleic acids to be detected and non-methylated nucleic acids to be detected, and the concentration of the methylated nucleic acids to be detected can be 75% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, less than 19%, 18% or less, 15% or less, 10% or less, 5% or less, 4.5% or less, 4% or less, 3.5% or less, 3% or less, 2.5% or less, 2% or less, 1.5% or less, 1.4% or less, 1.3% or less, 1.2% or less or 1.1% or less of the concentration of the non-methylated nucleic acids to be detected.

[0046] For example, the biological sample comprises a methylated nucleic acid to be detected and a non-methylated nucleic acid to be detected, and based on 100% of the total chains of the methylated nucleic acid to be detected and the non-methylated nucleic acid to be detected, it may comprise 100% or less, less than 100%, 99% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 46% or less, 48% or less, 50% or less, 51% or less, 52% or less, 53% or less, 54% or less, 55% or less, 56% or less, 57% or less, 58% or less, 59% or less, 60% or less, 61% or less, 62% or less, 63% or less, 64% or less, 65% or less, 66% or less, 67% or less, 68% or less, 69% or less, 70% or less, 71% or less, 72% or less, 73% or less, 74% or less, 75% or less, 76% or less, 77% or less, 78% or less, 79% or less, 80% or less, 81% or less, 82% or less, 83% or less, 84% or less, 85 ... 0% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, less than 10%, 5% or less, less than 5%, 4.5% or less, 4% or less, 3.5% or less, 3% or less, 2.5% or less, 2% or less, 1.5% or less, 1.4% or less, 1.3% or less, 1.2% or less, 1.1% or less, or 1% or less of the methylated nucleic acid to be detected.

[0047] For example, a biological sample can contain 20,000 or fewer, 15,000 or fewer, 10,000 or fewer, 5,000 or fewer, 4,000 or fewer, 3,000 or fewer, 2,000 or fewer, 1,000 or fewer, 500 or fewer, 400 or fewer, 300 or fewer, 200 or fewer, 150 or fewer, 100 or fewer, 90 or fewer, 80 or fewer, 70 or fewer, 60 or fewer, 50 or fewer, 40 or fewer, 30 or fewer, 20 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, or 3 or fewer methylated nucleic acids to be tested.

[0048] The method for determining whether the nucleic acid to be tested is methylated according to the embodiment of the present application may further include a quantitative step of the methylation level of the nucleic acid to be tested. The quantitative step may be to quantify the methylation level of the biological sample by comparing the AUC (area under the curve) of the melting curves of the biological sample, the sample in which the nucleic acid to be tested is 100% methylated, and the sample in which the nucleic acid to be tested is 100% non-methylated.

[0049] Specifically, the quantification step may include the step of obtaining a melting curve of the biological sample;

[0050] A step of obtaining a standardized melting curve of a biological sample in which the methylation ratio of the nucleic acid to be tested is identified; and a step of quantifying the methylation level of the biological sample by comparing the melting curve of the biological sample and the standardized melting curve. The melting curve of the biological sample can be a standardized melting curve. The melting curve of the biological sample can be obtained by HRM analysis. The methylation ratio of the nucleic acid to be tested can be obtained by the content ratio of the methylated nucleic acid to be tested and the non-methylated nucleic acid to be tested.

[0051] In other embodiments of the present application, the nucleic acid to be tested may include a biomarker for diagnosing cancer. Specifically, the nucleic acid to be tested may include a biomarker for diagnosing cancer, for example, a marker specifically methylated or non-methylated in a cancer patient, and the target site of the nucleic acid to be tested may be the position of a biomarker for diagnosing cancer. In this case, it can be used to diagnose cancer by determining whether the nucleic acid to be tested is methylated using a composition or method according to an embodiment of the present application.

[0052] Therefore, other embodiments of the present application relate to a composition for diagnosing cancer or a kit for diagnosing cancer, which comprises a composition for determining whether a nucleic acid to be tested is methylated according to an embodiment of the present application.

[0053] In addition, other embodiments of the present application relate to a method for diagnosing cancer or a method for providing information for diagnosing cancer, comprising a step of determining whether the nucleic acid to be tested is methylated by a method for determining whether the nucleic acid to be tested is methylated according to an embodiment of the present application. The method for diagnosing cancer or a method for providing information for diagnosing cancer may further comprise a step of comparing the methylation level of the nucleic acid to be tested with the methylation level of a control group.

[0054] The control group refers to nucleic acids isolated from biological samples of known origin, and all samples from subjects without liver cancer (normal control group) or subjects with liver cancer can be used.

[0055] For example, when a sample derived from a subject without liver cancer (normal control group) is used as a control group, when the methylation level of the nucleic acid to be tested is higher than the methylation level of the nucleic acid isolated from the control group, or when the biological sample contains a nucleic acid to be tested having a methylation level higher than that of the control group, it can be determined, diagnosed, or provide information for diagnosis: that is, the organism (e.g., vertebrates, mammals, rodents, goats, deer, pigs, birds, chickens, turkeys, cattle, horses, sheep, fish, primates, and as an example, humans) from which the nucleic acid to be tested or the biological sample is derived has cancer.

[0056] For example, in the case where a sample derived from a subject suffering from liver cancer is used as a control group, when the methylation level of the nucleic acid to be tested is similar to the methylation level of the nucleic acid isolated from the control group, or when the biological sample contains a nucleic acid to be tested having a methylation level similar to that of the control group, it can determine, diagnose, or provide information for diagnosis: that is, the organism (e.g., vertebrates, mammals, rodents, goats, deer, pigs, birds, chickens, turkeys, cattle, horses, sheep, fish, primates, and as an example, humans) from which the nucleic acid to be tested or the biological sample is derived has cancer.

[0057] The cancer may include at least one selected from the group consisting of liver cancer, colon cancer, esophageal cancer, stomach cancer, rectal cancer, colorectal cancer, oral cancer, pharyngeal cancer, laryngeal cancer, lung cancer, non-small cell lung cancer, colon cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, testicular cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, biliary tract cancer, bone cancer, connective tissue cancer, skin cancer, melanoma, brain cancer, head and neck cancer, thyroid cancer, leukemia, Hodgkin disease, lymphoma, urinary tract cancer and multiple myeloma blood cancer.

[0058] The liver cancer may be at least one selected from the group consisting of hepatocellular carcinoma, hepatoma, cholangiocarcinoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver tumor, hepatic angiosarcoma or metastatic liver cancer, vague nodular HCC, and hypovascular liver cancer.

[0059] Other embodiments of the present application relate to methods for treating cancer, which include treating a subject determined to have cancer by a composition for diagnosing cancer, a kit for diagnosing cancer, a method for diagnosing cancer, or a method for providing information for diagnosing cancer according to an embodiment of the present application. The treatment step may include administering an effective amount of a therapeutic agent, chemotherapy, hormone therapy, radiotherapy, surgery, or a combination thereof to the subject.

[0060] The therapeutic agent may include, for example, afatinib, AK105, anlotinib, apatinib, atezolizumab, avelumab, axitinib, bevacizumab, bosutinib, BSC, cabozantinib, cabozantinib-S-malate, carrelizumab, canertinib, carboplatin, capecitabine, celecoxib, CC-122, CF102, crizotinib, dasatinib, docetaxel, donafenib, dovitinib, doxorubicin, durvalumab, EKB-569, entrectinib, epirubicin, erlotinib, etoposide, everolimus, FGF401, FOLFOX 4. Fostamatinib, Galunisertib, Gefitinib, Gemcitabine, IBI305, Ibrutinib, Imatinib, INC280, Infigratinib, Ipilimumab, Irinotecan, Lapatinib, Leflunomide, Lenvatinib, LY2875358, Mesylate, Mitomycin C, MSC2156119J, Neratinib, Nilotinib, Nintedanib, Nivolumab, Oxaliplatin, Palbociclib, Panobinostat, Pazopanib, PDR001, Pa Bolizumab, pemitinib, Pexavec, phosphate, ramucirumab, regorafenib, ruxolitinib, semasanib, selumetinib, SGO-110, SHR-1210, sintilimab, sorafenib, SU6656, sunitinib, sintilimab, spartalizumab, sutent, TACE, taquimod, temozolomide, temsirolimus, tislelizumab, tivantinib, tosylate, toripalimab, simumab, vandetanib, vatalanib, XL888, Y90, a pharmaceutically acceptable salt thereof, or a combination thereof.

[0061]

Beneficial effects

[0062] The embodiments of the present application can construct a new experimental validation method design by making up for the deficiencies of conventional qMSP, MethyLight and MS-HRM analysis methods, and can detect DNA methylation markers through liquid biopsy, and have higher sensitivity than conventional MS-HRM analysis methods, and can quantify methylation levels.

[0063] One embodiment of the present application can perform PCR at a more sensitive level for targets with extremely low content (such as circulating tumor DNA present in the blood), and the experiment can be designed by adjusting the degree of binding of methylated primers and non-methylated primers to the template according to the use that depends on the annealing temperature and the concentration ratio of the primers. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1a to Figure 1c It is a diagram showing the experimental results of conventional MS-HRM analysis using MIP (methylation-independent primers).

[0065] Figure 2a to Figure 2c The figure shows the results of an attempt to improve by including CpG at the 5′ end of the primer to suppress non-methylation-biased amplification occurring during PCR amplification using MIP.

[0066] Figure 3a and Figure 3b This is a diagram confirming the phenomenon of interference with marker amplification when using a fluorescent probe for methylite analysis and the like.

[0067] Figures 4a to 4c This is a diagram showing the results of MS-HRM analysis using a mixture of methylated primers and non-methylated primers.

[0068] Figure 5a It is a graph showing the distribution of melting peaks for each sample according to the methylation ratio of the sample.

[0069] Figure 5b This is a graph showing the results of HRM analysis of each sample by melting curve analysis according to the methylation ratio of the sample.

[0070] Figure 6a This is a graph that confirms whether quantitative amplification occurs when methylated primers and non-methylated primers are mixed in one tube.

[0071] Figure 6b It is a graph showing the results of confirming the accuracy of methylation ratio measurement using mAUC (melting curve area under the curve) representing the methylation ratio.

[0072] Figure 6c It is a graph confirming that the method for determining the methylation status according to the embodiment of the present application can distinguish between the methylated DNA concentration 1% level (3 methylated DNAs) and 0% concentration, and can detect 1% methylated DNA in a sample in which non-methylated DNA is present at a concentration of 99%.

[0073] Figure 7 This is a diagram for confirming whether biased amplification of methylated DNA occurs depending on the concentration ratio of the methylated primer and the non-methylated primer.

[0074] Figure 8a and Figure 8b : is a diagram showing preliminary clinical results of diagnosing cancer by applying the method for determining the methylation state according to an example of the present invention to actual blood. DETAILED DESCRIPTION

[0075] Hereinafter, the present application will be described in more detail by the following examples. However, these examples are only used to illustrate the present invention, and the scope of the present application is not limited by these examples.

[0076] Comparative Example 1. Limitations of conventional MS-HRM analysis methods

[0077] As an example of nucleic acid to be tested, a nucleic acid having a sequence of SEQ ID NO: 1 was used to confirm the limitations of conventional MS-HRM analysis methods. The nucleic acid sequence of SEQ ID NO: 1 is a liver cancer biomarker specifically methylated in liver cancer cells. DNA isolated from liver cancer cells may contain methylated nucleic acids of SEQ ID NO: 1, and DNA isolated from other cells may contain non-methylated nucleic acids of SEQ ID NO: 1. Various samples and control samples containing nucleic acids of SEQ ID NO: 1 were prepared as shown in Table 1 and used in the experiment. Samples No. 2 to 4 were purchased from Qiagen and used, sample No. 2 was obtained by converting all cytosines to thymines by treating the gDNA of sample No. 3 with sulfite using an EpiTect bisulfite kit, and sample No. 4 was obtained by converting cytosines other than CpG cytosines to thymines by treating the gDNA of sample No. 3 with sulfite conversion using an EpiTect bisulfite kit after 100% methylation using an SssI methylase. Prior to the PCR reaction, the samples of sample numbers 5 to 7 were treated with sulfurous acid and non-methylated cytosine was converted to thymine.

[0078]

Table 1

[0079]

[0080]

[0081] Conventional MS-HRM analysis uses methylation-independent primers (MIPs) that do not contain CpG and TpG recognition sites to non-selectively amplify methylated nucleic acids and non-methylated nucleic acids treated with sulfite. The sequences of the methylation-independent primers used are as follows:

[0082] -Forward: gTtgTatTatTtgTTaggggTtgT (SEQ ID NO:7)

[0083] - Reverse: ccacaAAAcctccaAAcaAtAA (SEQ ID NO: 8)

[0084] The MS-HRM Master Mix was prepared by mixing the components of Table 2. The dosage described in Table 2 was the amount required for one sample, and when multiple samples were tested, a Master Mix at the level of the number of samples + 2 (22 μL / rxn) was prepared and used.

[0085]

Table 2

[0086]

[0087] The prepared Master Mix was equally distributed in a 96-well PCR plate ( PCR plate, Biorad) in each well, 22 μL in each well. The seven samples according to Table 1 were prepared to have a concentration of 0.33 ng / μL and aliquoted in each well, 3 μL in each well, so that the total DNA amount was 1 ng. The PCR reaction was performed once at 95°C for 5 minutes using a CFX96Touch real-time PCR detection system (BioRad), and the following cycles were repeated 50 times: 95°C denaturation temperature for 20 seconds, 60°C heating and cooling temperature for 30 seconds, and 72°C extension temperature for 30 seconds. In addition, the fluorescence value of each cycle was confirmed by measuring fluorescence before the extension temperature was started after the heating and cooling temperature lasted for 30 seconds. After the PCR reaction was completed, after a 5-minute stabilization period at 72°C, a melting analysis was performed, which confirmed the degree of binding of the amplified product according to the increase in temperature, and HRM analysis was performed by measuring the fluorescence intensity at intervals of 10 seconds, while the temperature was increased from 65°C to 95°C in increments of 0.2°C.

[0088] Confirm the fluorescence values ​​of PCR and HRM analysis, and confirm the melting curve or peak to determine the characteristics of each sample. In addition, after completing PCR, perform electrophoresis and confirm that the size of the amplified product is accurately produced by the designed primers.

[0089] like Figure 1aAs shown, the amplification of the 100% methylated nucleic acid sample to be tested (EpiTect Met sample number 4) and the 100% unmethylated nucleic acid sample to be tested (EpiTect Unmet; sample number 2) was almost similar. In addition, they were amplified with similar efficiency in liver cancer cells (Huh-1; sample number 6), kidney cells (Hek293T; sample number 5) and blood cells (PBMC; sample number 7), and the increase in the fluorescence RFU value of PCR confirmed that both the methylated nucleic acid to be tested and the unmethylated nucleic acid to be tested were amplified. However, there is a problem of non-specific amplification occurring by the binding of MIP, even in the control group (EpiTect gDNA; sample number 3) that was not treated with sulfite and the control group (NTC; sample number 1) that should not be amplified.

[0090] like Figure 1b As shown in FIG. 1 , high resolution melting curve (HRM) analysis can confirm that the amplified DNA is methylated markers, unmethylated markers, and nonspecific MIP amplified DNA. Figure 1c The electrophoresis results shown confirm the presence of a large amount of non-specifically amplified DNA.

[0091] Therefore, the conventional MS-HRM analysis method has problems in that the genomic DNA sequence is simplified by treatment with sulfurous acid, and nonspecific amplification products are often generated due to the simplicity of the MIP primer sequence consisting only of adenine, guanine, and thymine, and amplification of the target nucleic acid is limited.

[0092] Comparative Example 2. Limitations of the MS-HRM analysis method using primers with added CpG recognition sites to prevent biased amplification of non-methylated nucleic acids

[0093] In order to suppress the non-methylation biased amplification that occurs during the PCDR amplification process using methylation-independent primers, a CpG sequence is included at the 5' end of the primer for improvement. The MIP primers used in Example 1 were changed to the following primers, and PCR was performed on the samples of sample numbers 2, 3, 4 and 6 in Table 1 by the same method, and HRM analysis and electrophoresis were performed. The sequences of the primers used are as follows:

[0094] -Forward: TTtCGgTtgTatTatTtgTTaggggT (SEQ ID NO:9)

[0095] - Reverse: AACGccccacaAAAcctccaAA (SEQ ID NO: 10)

[0096] like Figure 2aAs shown in Figure 2, due to the bias, methylated DNA can be amplified more favorably by adding CpG to the 5' end of MIP. The results showed that the 100% methylated sample (EpiTect Met; sample number 4) and liver cancer cell DNA (Huh-1; sample number 6) were effectively amplified, while the unmethylated DNA sample (EpiTect Unmet; sample number 2) and the control group not treated with sulfite (Epitect gDNA; sample number 3) were not amplified. However, as Figure 2b The HRM analysis results and Figure 2c As shown in the electrophoresis analysis results of , non-specific amplification occurred in the non-methylated samples. Therefore, when the non-methylated samples are analyzed under conditions where the bias is increased by methylation, there is a problem that the non-specific amplification is very high.

[0097] Comparative Example 3. Limitations of MS-HRM analysis using fluorescent probes

[0098] When the PCR amplification efficiency was confirmed when the fluorescent probe for Methylite analysis and the like was used as Comparative Example 1, the results of MS-HRM on a liver cancer sample (Huh-1; sample number 2) and a 100% methylated sample (EpiTect Met; sample number 1) were shown in FIG. Figure 3a The results are shown in Table 2. Figure 3b In each experiment, a sample without bisulfite treatment (EpiTect gDNA; sample number 3) was used as a control.

[0099] Figure 3a It is the result of measuring the amount of amplified DNA (expressed as PCR Cq value) when no fluorescent probe that specifically binds to the methylated nucleic acid to be detected is added. Figure 3b This is the result of adding the fluorescent probe. Figure 3b As shown, the Cq value increased by about 4 due to the fluorescent probe, so there was a problem of a 10- to 20-fold decrease in amplification efficiency.

[0100] Example 1. Preparation of methylated primers and non-methylated primers

[0101] Primers for determining whether a nucleic acid having a sequence of SEQ ID NO: 1 is methylated were prepared as an example of a nucleic acid to be tested. The nucleic acid sequence of SEQ ID NO: 1 is shown in Table 3, with the target site indicated in italics and the primer binding site indicated by underscores. In the sequence of SEQ ID NO: 1, CpG and non-CpG cytosine are written in uppercase letters, and other bases are written in lowercase letters. In the sequence of SEQ ID NO: 1, the CpG sequence is shown in bold.

[0102] The methylated nucleic acid sequence of SEQ ID NO: 1 is represented by the nucleic acid sequence after sulfite treatment as SEQ ID NO: 2, and the non-methylated nucleic acid sequence of SEQ ID NO: 1 is represented by the nucleic acid sequence after sulfite treatment as SEQ ID NO: 3. In SEQ ID NO: 2 and SEQ ID NO: 3, bases that differ due to sulfite treatment are represented in bold according to the methylation state of CpG cytosine.

[0103] Considering the sequence of the template to be converted after treatment with sulfite, one of the forward or reverse primers should contain a CpG or TpG sequence near the 3' end so as to specifically bind to one of the methylated template or the non-methylated template. The methylated template is not converted from CpG cytosine to thymine after treatment with sulfite and is retained, so the methylated primer is designed to contain a CpG recognition site that recognizes the CpG sequence, and the non-methylated primer is designed to contain a TpG recognition site that recognizes the TpG sequence. At this time, since the primer that specifically binds to the non-methylated template has a lower Tm than the primer that specifically binds to the methylated template, in order to compensate for this, nucleotides can be added to the 5' end. The primer in the opposite direction to the methylated primer and the non-methylated primer is designed to be a primer that can bind regardless of the methylation state of the methylated chain and the non-methylated chain. By containing 2 or more non-CpG cytosines, all primers can specifically bind to the DNA chain converted by sulfite.

[0104] The forward primer is designed to bind to nucleic acid positions 147-171 in the nucleic acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3, and the reverse primer is designed to bind to nucleic acid positions 206-229 in the nucleic acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3. The primer binding sites of SEQ ID NO: 2 or SEQ ID NO: 3 are underlined.

[0105] Two forward primers were prepared, namely a methylated primer capable of binding to nucleic acid positions 147-171 in the nucleic acid sequence of SEQ ID NO: 2, and a non-methylated primer capable of binding to nucleic acid positions 206-229 in the nucleic acid sequence of SEQ ID NO: 3. At this time, the reverse primer is a universal reverse primer capable of binding to both the sulfite-treated methylated nucleic acid to be tested and the sulfite-treated non-methylated nucleic acid to be tested.

[0106] The sequences of the prepared primers are shown in Table 3. In the sequences of the methylated primer and the unmethylated primer, the sequences that differ depending on whether the nucleic acid to be detected is methylated are underlined.

[0107]

Table 3

[0108]

[0109]

[0110] Example 2. MS-HRM using methylated and unmethylated primers

[0111] MS-HRM analysis was performed using the primers prepared in Example 1. MS-HRM Master Mix was prepared by mixing the components of Table 4. The dosage described in Table 4 is the amount required for one sample, and when multiple samples were tested, Master Mix (22 μL / rxn) at the level of the number of samples + 2 was prepared and used.

[0112]

Table 4

[0113]

[0114] Various samples and control samples comprising the nucleic acid of SEQ ID NO: 1 were prepared as shown in Table 5 and used in the experiment.

[0115]

Table 5

[0116] Sample No. Sample name Sample description Methylation or not 1 NTC Non-template control - 2 EpiTect gDNA Samples without sulfite treatment - 3 EpiTect Unmet.DNA 100% non-methylated samples X 4 Healthy PBMCs Samples from normal blood cells X 5 EpiTect Met. 100% methylated sample O 6 Huh-1 Samples from liver cancer cells O

[0117] The prepared Master Mix was equally distributed in a 96-well PCR plate ( PCR plate, Biorad), 22 μL per well. Six samples according to Table 5 were prepared to have a concentration of 0.33 ng / μL, and 3 μL was aliquoted in each well so that the total DNA amount was 1 ng.

[0118] The PCR reaction was performed once at 95°C for 5 minutes using a CFX96 Touch real-time PCR detection system (BioRad), and the following cycle was repeated 50 times: 95°C denaturation temperature for 20 seconds, 60°C heating and cooling temperature for 30 seconds, and 72°C extension temperature for 30 seconds. In addition, the fluorescence value of each cycle was confirmed by measuring fluorescence before the extension temperature was started after 30 seconds of heating and cooling temperature. After the completion of the PCR reaction, after a 5-minute stabilization period at 72°C, a melting analysis was performed, which confirmed the degree of binding of the amplified product according to the increase in temperature, and HRM analysis was performed by measuring the fluorescence intensity at intervals of 10 seconds while the temperature was increased from 65°C to 95°C in increments of 0.2°C.

[0119] Confirm the fluorescence values ​​of PCR and HRM analysis, and confirm the melting curve or peak to determine the characteristics of each sample. In addition, after completing PCR, perform electrophoresis and confirm that the size of the amplified product is accurately generated by the designed primers.

[0120] Methylated primers and unmethylated primers are added to a sample at the same time, and the nucleic acid to be tested is amplified under the condition that methylated DNA and unmethylated DNA can be amplified together. Figure 4a As shown, amplification occurred equally in sulfite-treated methylated DNA (Epitect Met and Huh-1) and unmethylated DNA (Epitect UnMet and PBMC), whereas no amplification occurred in control samples (NTC and EpiTect gDNA without sulfite treatment). Figure 4b The HRM analysis results and Figure 4c Only specific amplification occurred in the electrophoresis analysis results.

[0121] Example 3. Detection limit and quantification of methylation levels

[0122] To determine the minimum detection limit of the sample methylation ratio, samples with a methylation ratio of 50%, 25%, 12.5%, or 6.25% were prepared by mixing PBMC (0.33 ng / μL) and Huh-1 (0.33 ng / μL) and used in the experiment. Each methylation ratio sample was aliquoted in 3 μL in each well, and PCR reaction and HRR analysis were performed by the same method as in Example 2, and the results are shown in Figure 5a and Figure 5b middle.

[0123] Figure 5aThe melting peak distribution of each sample obtained by analyzing 1 ng of DNA by the primer mix MS-HRM method after mixing sulfite-treated liver cancer cell DNA and sulfite-treated blood cell DNA in the presented ratios is shown. It can be seen that the size and ratio of the melting peak of methylated DNA and the melting peak of unmethylated DNA gradually change according to the ratio of methylated Huh-1 DNA.

[0124] Figure 5b It is a graph showing the results of HRM analysis by melting curve analysis. It shows that the slope of the melting curve increases slowly with the increase of liver cancer cell DNA and is between the slope of non-methylated blood cells and the slope of 100% methylated liver cancer cells. Therefore, the area under the curve (AUC) of the melting curve can be calculated to quantitatively evaluate the methylation ratio. Specifically, the methylation level can be quantified by calculating a percentage, which is obtained by dividing the difference between the AUC values ​​of the melting curves of the unknown sample and the completely non-methylated control group by the difference between the AUC values ​​of the melting curves of the completely methylated control sample and the completely non-methylated control sample.

[0125] More specifically, in order to remove the exponential background noise from the total fluorescence value according to the temperature, the temperature at which the MS-HRM fluorescence change rate is kept constant is selected in the interval below and above the melting temperature (Tm) (each TL, TR), and the parameters of the exponential background noise are estimated from the fluorescence change rate (dF / dT) at each point. The fluorescence data function M(T) proportional to the amount of residual dsDNA is calculated by removing the exponential background noise value calculated from the estimated parameters from the total fluorescence value at each temperature point. For M(T), minimum-maximum normalization is performed in the temperature interval of [TL, TR] to calculate the residual dsDNA ratio function M1(T) according to the increase in temperature. In order to obtain the methylation level, the area under the curve (AUC) value S of M1(T) in the interval [TL, TR] is calculated from each sample, and then the methylation level of the sample can be determined based on the S value.

[0126] Example 4. Detection sensitivity

[0127] Since ctDNA exists in the blood at a very low concentration, in order to confirm whether the method for determining whether methylation is present according to the embodiment of the present application can be used for cancer diagnosis based on actual blood testing, the detection limit was confirmed.

[0128] In order to confirm the minimum DNA chain that can be confirmed by the method for determining whether methylation is present according to the embodiment of the present application, PBMC and Huh-1 (50 ng / 3 μL) samples were diluted with NFW to prepare Huh-1 samples with a concentration of 50, 30, 10, 5, 3, 1, 0.5, 0.3, 0.1, 0.05 or 0.01 ng / 3 μL. Each concentration of the sample was equally divided into 3 μL in each well, and PCR reaction and HRR analysis were performed by the same method as in Example 2.

[0129] MS-HRM analysis of methylated and non-methylated primer combinations was performed using 5000-fold differences in the amount of sulfite-treated liver cancer cell DNA from 0.01 ng to 50 ng. The amount of the amplified nucleic acid to be tested was analyzed by measuring the PCR Cq value and displayed in Figure 6a In. Figure 6a As shown in the figure, as a result of increasing the amount of DNA while amplifying, the Cq value of about 38 when using 0.01 ng (3 strands) of DNA was increased to 50 ng (15200 strands), and the results showed that the decrease in the Cq value was exactly the same as the increase in the amount of DNA. As a result, it can be seen that the MS-HRM analysis using the combination of methylated primers and non-methylated primers effectively amplified even 0.01 ng of DNA, and effectively amplified it over a wide region of 5000 times.

[0130] Figure 6b The results show whether the methylation ratio can be accurately measured when analyzing various amounts of DNA using mAUC (melting curve area under the curve) showing the methylation ratio. Figure 6b As shown, the difference in AUC values ​​does not increase depending on the amount of each sample, and is consistently confirmed, and the amplification product of each sample is the nucleic acid to be tested, and the methylation level of each sample can be measured. Therefore, even in a sample containing at least 3 nucleic acid chains to be tested, the methylation state of the nucleic acid to be tested can be measured.

[0131] In addition, in order to confirm that the method for determining whether methylation is present according to the embodiment of the present application is capable of determining the minimum ratio of the target methylated DNA in the presence of non-methylated DNA, samples of 0, 1, 2, 4, 8, 16, 32, and 100% were prepared by serially diluting non-methylated DNA and methylated DNA, and MS-HRM analysis was performed, and the correlation of the AUC value according to the change in the ratio was confirmed and displayed in Figure 6c middle.

[0132] like Figure 6cAs shown, as a result of confirming the detectable minimum ratio under the condition of presence of non-methylated DNA, it can be confirmed that there is a difference between 1% methylated DNA concentration (3 methylated DNAs) and 0% methylated DNA concentration, and a high R value can be confirmed even in the correlation analysis between the AUC value and the methylated DNA ratio.

[0133] Therefore, it was confirmed that the method for determining whether or not methylation is performed according to the embodiment of the present application has high detection sensitivity and can detect 1% of methylated DNA even in a sample in which 99% of non-methylated DNA exists.

[0134] Example 6. Improving detection sensitivity by non-methylated primers

[0135] To confirm whether the unmethylated primers improve the detection sensitivity, samples of Huh-1 6.25, 25.0, 50.0 or 100.0% were used. As described in Example 5, in the components of Table 3, the volume of the unmethylated forward primer was changed to 1, 0.75, 0.5 or 0.25 μL, and correspondingly, the volume of NFW was changed to 5.25, 5.50, 5.75 or 6 μL.

[0136] We confirmed whether methylated DNA was preferentially amplified depending on the concentration ratio of the methylated primer to the unmethylated primer. PCR was performed under the conditions where the amount of the methylated primer was fixed at 0.4 μM and the amount of the unmethylated primer was decreased to 0.4, 0.3, 0.2, and 0.1 μM.

[0137] like Figure 7 As shown, when the proportion of methylated DNA in liver cancer cells was as low as 25% or less and the amount of unmethylated primers was 50% or less of that of methylated primers, the detection sensitivity of methylated DNA was further increased.

[0138] Therefore, since the detection sensitivity is improved by using the methylated primer and the non-methylated primer in combination, it is possible to confirm whether low-concentration methylated DNA (eg, cfDNA) is methylated.

[0139] Example 7. Cancer Diagnosis by Measuring Methylation of Cancer Biomarkers in Blood

[0140] A preliminary clinical trial was conducted to confirm whether the methylation status of a nucleic acid to be tested can be determined by applying MS-HRM analysis using a combination of methylated primers and non-methylated primers to actual blood.

[0141] After extracting 10 mL of blood from healthy people and liver cancer patients, the serum was separated using a centrifuge (1900 g, 15 minutes). According to the manufacturer's recommended method, cfDNA was extracted from the separated serum using the MagListoTM cfDNA extraction kit (Bioneer). For the extracted cfDNA, the EZ DNA Methylation-Lightning kit (Zymo Research) was used for sulfite conversion for MS-HRM analysis according to the manufacturer's recommended method. For sulfite-converted cfDNA, MS-HRM analysis was performed through the following steps.

[0142] Prepare MS-HRM Master Mix according to Table 3, and divide the prepared Master Mix into 96-well PCR plates ( PCR plate, Biorad) in each well, 22 μL per well, and PCR reaction and HRR analysis were performed by the same method as in Example 2. The fluorescence values ​​used for PCR and HRM analysis were confirmed, and the melting curve or peak was confirmed to determine the methylation levels of healthy people and liver cancer patients.

[0143] Figure 8a This is a graph showing the results of primer combination MS-HRM using about 1 ng of cfDNA after collecting 2 ml of blood from 92 healthy people and 119 liver cancer patients to separate plasma, and separating cfDNA from it and treating it with sulfite. The analysis results of the healthy people (green) show low-temperature melting peaks, all of which are non-methylated, while the blood samples of liver cancer patients (red) show high-temperature melting peaks.

[0144] Figure 8b It is a graph showing the experimental results represented by melting curve analysis of the test nucleic acid of SEQ ID NO: 1 using a combined MS-HRM method for blood of normal people and liver cancer patients. Normal people (green) are non-methylated, so the amplified DNA melts quickly and shows a steeper curve slope, while blood samples of liver cancer patients (red) contain cancer DNA, which has a high melting point due to the amplification of methylated cancer DNA, so it shows a relatively gentle melting curve slope. It can be confirmed that about 60% or more of the cfDNA of liver cancer patients contains higher methylated DNA than the cfDNA of the normal population. Therefore, by detecting a very small amount of nucleic acid (such as cfDNA), such as methylated cfDNA with a very small fragment of about 100bp, trace methylation marker DNA present in the blood can be effectively detected.

Claims

1. A composition for determining whether a nucleic acid to be tested is methylated, A primer set comprising a target site for amplifying the nucleic acid to be detected, The primer set comprises (1) a methylated forward primer, a non-methylated forward primer, and a universal reverse primer; or (2) Universal forward primer, methylated reverse primer and unmethylated reverse primer, The methylation forward primer and the methylation reverse primer comprise a CpG recognition site, and the CpG recognition site recognizes the CpG sequence of the nucleic acid to be tested. wherein the unmethylated forward primer and the unmethylated reverse primer comprise a TpG recognition site, the TpG recognition site recognizes the TpG sequence of the nucleic acid to be tested, and The TpG sequence is transformed from the CpG sequence of the nucleic acid to be detected.

2. The composition according to claim 1, wherein the TpG sequence is converted by a reagent that modifies the methylated nucleic acid to be detected and the non-methylated nucleic acid to be detected to be different from each other.

3. The composition of claim 2, wherein the agent converts non-methylated cytosine residues to thymine.

4. The composition according to claim 2, wherein the agent is at least one selected from the group consisting of sulfurous acid, bisulfite, hydrosulfite and pyrosulfite. 5 . The composition according to claim 1 , wherein the CpG recognition site or TpG recognition site is located within 40 bases of the 3′ end of the methylated forward primer, the methylated reverse primer, the unmethylated forward primer or the unmethylated reverse primer.

6. The composition of claim 1, wherein the target site comprises a CpG sequence.

7. The composition of claim 1, wherein the target site is 50 to 150 bp in size.

8. The composition of claim 1, wherein the size of the primer comprises 15 to 40 bases.

9. The composition according to claim 1, wherein the common reverse primer or the common forward primer comprises 5 or less CpG or TpG recognition sites of the nucleic acid to be detected.

10. The composition according to claim 1, wherein the difference in Tm between the methylated forward primer and the unmethylated forward primer of (1); or the difference in Tm between the methylated reverse primer and the unmethylated reverse primer of (2) is 15°C or less.

11. The composition according to claim 1, wherein the (1) the methylated forward primer and the non-methylated forward primer; or (2) The concentration ratio of the methylated reverse primer to the non-methylated reverse primer is 100:1 to 1:

100.

12. The composition according to claim 1, wherein the nucleic acid to be detected is contained in a biological sample.

13. The composition according to claim 12, wherein the biological sample comprises at least one selected from the group consisting of blood, serum, tissue, cells, feces and urine. The composition according to claim 12 , wherein the biological sample comprises methylated nucleic acids to be detected and non-methylated nucleic acids to be detected. 15 . The composition according to claim 14 , wherein the concentration of the methylated nucleic acid to be detected is 75% or less of the concentration of the non-methylated nucleic acid to be detected.

16. The composition according to claim 1, wherein the nucleic acid to be detected comprises a biomarker for diagnosing cancer.

17. The composition of claim 16, wherein the cancer can include at least one selected from the group consisting of liver cancer, colon cancer, esophageal cancer, gastric cancer, rectal cancer, colorectal cancer, oral cancer, pharyngeal cancer, laryngeal cancer, lung cancer, non-small cell lung cancer, colon cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, testicular cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, bile duct cancer, bone cancer, connective tissue cancer, skin cancer, melanoma, brain cancer, head and neck cancer, thyroid cancer, leukemia, Hodgkin's disease, lymphoma, urinary tract cancer, and multiple myeloma blood cancer.

18. The composition of claim 1, wherein the target site is a biomarker located in a CpG island.

19. A method for determining whether a nucleic acid to be tested is methylated, comprising A step of modifying the methylated nucleic acid to be detected and the non-methylated nucleic acid to be detected to be different from each other, wherein the nucleic acid to be detected is contained in the biological sample; and A step of amplifying the target site by treating the biological sample with the composition of any one of claims 1 to 18.

20. The method according to claim 19, wherein the modification is performed by treating the biological sample with a reagent that modifies the methylated nucleic acid to be detected and the non-methylated nucleic acid to be detected to be different from each other.

21. The method according to claim 19, wherein the biological sample is at least one selected from the group consisting of blood, serum, tissue, cells, feces and urine.

22. The method according to claim 19, further comprising the step of quantifying the methylation level of the nucleic acid to be tested.

23. The method according to claim 22, wherein the quantification step is to quantify the methylation level of the biological sample by comparing the AUC (area under the curve) of the standardized melting curves of the biological sample, the sample in which the nucleic acid to be tested is 100% methylated, and the sample in which the nucleic acid to be tested is 100% non-methylated.

24. The method according to claim 19, further comprising A step of obtaining a melting curve of the biological sample; A step of obtaining a standardized melting curve of a biological sample identifying the methylation ratio of a nucleic acid to be tested; and The step of quantifying the methylation level of the biological sample by comparing the melting curve of the biological sample with the standardized melting curve.

25. The method of claim 19, wherein the target site comprises a biomarker located in a CpG island.

26. A method for providing information for diagnosing cancer, comprising A step of modifying the methylated nucleic acid to be detected and the non-methylated nucleic acid to be detected in the nucleic acid to be detected contained in the biological sample to be different from each other; A step of amplifying by treating the biological sample with a composition according to any one of claims 1 to 18; and The step of determining whether the nucleic acid to be tested is methylated, The nucleic acid to be detected includes a biomarker for diagnosing cancer.

27. The method of claim 26, wherein the biomarker nucleic acid for diagnosing cancer is methylated or unmethylated in a cancer patient.

28. The method according to claim 26, further comprising the step of comparing the methylation level of the nucleic acid to be tested with the methylation level of a control group.

29. The method of claim 26, wherein the cancer comprises one or more selected from the group consisting of: Liver cancer, colorectal cancer, esophageal cancer, stomach cancer, rectal cancer, oral cancer, pharyngeal cancer, laryngeal cancer, lung cancer, colon cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, testicular cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, bone cancer, connective tissue cancer, skin cancer, brain cancer, head and neck cancer, thyroid cancer, leukemia, Hodgkin's disease, lymphoma and multiple myeloma blood cancer.

30. The method of claim 26, wherein the biomarker for diagnosing cancer is located in a CpG island.

31. A kit for determining whether a nucleic acid to be tested is methylated, comprising the composition according to any one of claims 1 to 18.

32. A composition for diagnosing cancer, comprising the composition according to any one of claims 1 to 18, wherein the nucleic acid to be detected comprises a cancer biomarker.

33. A kit for diagnosing cancer, comprising the composition according to claim 30.